Dr. Weisman Quoted in NY Times Article on Aducanumab
Medicare should require safety monitoring and medical expertise in the use of aducanumab.
Dr. Weisman Quoted in NY Times Article on Aducanumab Read More »
Medicare should require safety monitoring and medical expertise in the use of aducanumab.
Dr. Weisman Quoted in NY Times Article on Aducanumab Read More »
While we might not have clear progress, we do have an advance.
Aducanumab: Neither Far Nor Deep Read More »
It was once so common to be forgetful in old age that it was thought to be normal. But normal aging only includes things like tip-of-tongue memory loss and forgetting faces.
Alzheimer’s Disease: Mystery No More Read More »
Dr. Weisman discusses COVID-19, Alzheimer’s disease, and clinical research with Jerry Rothkoff.
Dr. Weisman interviewed on Senior Advocates, Who’s Who Read More »
Dr. Weisman has been interviewed in a new article in Neurology Insights regarding the unique challenges faced by Alzheimer’s patients and caregivers during the pandemic.
Dr. Weisman interviewed in Neurology Insights Read More »
In many ways we’ve been fortunate. Despite a pandemic, society has not broken down.
The Pandemic Will End: How and Why Read More »
Aducanumab, the first Alzheimer’s-modifying therapy, submitted to the FDA. Can Biogen recover from their errors?
Alzheimer’s Patient Newsletter February 2020 Read More »
“If you have a loved one with dementia, you know this can be a heart-wrenching process. You cannot change the person. . . . You have to meet them where they are, roll with it, and speak with love and patience. It was a pleasure to speak to Dr. David Weisman, a neurologist.”
Dr. Weisman interviewed on Boomer Living podcast Read More »
The field of MS research has had amazing success in the last two decades.
MS Patient Newsletter December 2019 Read More »
Multiple sclerosis (MS) is an autoimmune disease in which the immune system misrecognizes part of the brain called myelin.
MS Physician Newsletter October 2019 Read More »